Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction

NCT ID: NCT02255669

Last Updated: 2015-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the duration of stent patency between partially covered and fully covered SEMS for palliation of malignant distal bile duct obstruction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Endoscopic stent placement has been used as a principle palliative method in patients with unresectable distal malignancy biliary obstruction. It has been pivotal in providing relief from obstructive jaundice, improving the quality of life, and allowing the maintenance of chemotherapy. Although SEMSs have been reported to be superior to plastic stents in terms of stent patency, they still have some debatable issues ; in uncovered SEMS, stent occlusion due to epithelial hyperplasia and tumor ingrowth through the metal mesh is a frequent problem, whereas covered SEMSs are prone to migration.

The aim of the current study is to compare the duration of stent patency between partially covered and fully covered SEMS as a primary objective, and investigate overall patient survival, stent occlusion rate, and incidence of adverse events including stent dysfunction as secondary objectives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biliary Tract Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

partially covered SEMS

Deployment of Partially covered biliary self expandable metal stent

Group Type ACTIVE_COMPARATOR

partially covered SEMS

Intervention Type DEVICE

Used for palliation of inoperable malignant distal bile duct obstruction.

fully covered SEMS

Deployment of Fully covered biliary self expandable metal stent

Group Type ACTIVE_COMPARATOR

fully covered SEMS

Intervention Type DEVICE

Used for palliation of inoperable malignant distal bile duct obstruction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

partially covered SEMS

Used for palliation of inoperable malignant distal bile duct obstruction.

Intervention Type DEVICE

fully covered SEMS

Used for palliation of inoperable malignant distal bile duct obstruction.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Insertion of partially covered SEMS (PCSEMS) Insertion of fully covered SEMS (FCSEMS)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.\> 19years 2.malignant biliary obstruction, 2 cm distal to hilum 3.unsuitable for curative surgical resection owing to metastasis, locally advanced stage, high operation risk, or patient's refusal

Exclusion Criteria

* 1.history of biliary surgery except cholecystectomy 2.history of SEMS placement 3.coagulopathy (INR\>1.5, Platelet\<50000) 4.expected survival \> 3 months based on Karnofsky performance score 5.duodenal stricture
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Samsung Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jong Kyun Lee, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Cencer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samsung Medical Cencer

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jong Kyun Lee, M.D., Ph.D.

Role: CONTACT

82-2-3410-3409

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jong-Kyun Lee, M.D., Ph.D.

Role: primary

81-2-3410-3409

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-07-187-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.